Affinage

DOCK2

Dedicator of cytokinesis protein 2 · UniProt Q92608

Length
1830 aa
Mass
211.9 kDa
Annotated
2026-06-09
100 papers in source corpus 39 papers cited in narrative 39 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DOCK2 is a hematopoietic cell-enriched, atypical guanine nucleotide exchange factor that serves as the central activator of Rac GTPases (Rac1 and Rac2) driving actin-dependent cytoskeletal reorganization throughout the immune system (PMID:11518968, PMID:10559471, PMID:16943182). In lymphocytes, DOCK2 is required for chemokine-induced Rac activation and actin polymerization, and its loss abolishes chemotaxis (PMID:11518968). DOCK2 functions as an obligate partner of ELMO1: it binds ELMO1 through its SH3 domain, and this association is required for Rac activation and actin polymerization, mutually relieving autoinhibition in both proteins and protecting DOCK2 from polyubiquitination and proteasomal degradation (PMID:12829596, PMID:22331897, PMID:24821968, PMID:32651375). Catalysis is executed by the DHR-2 domain, whose activity additionally requires lobe A-mediated dimerization for efficient Rac engagement at the membrane (PMID:22520755, PMID:23050005). DOCK2 is recruited to the plasma membrane and leading edge by PIP3 in a PI3K-dependent manner, generating spatially defined pools of active Rac that pattern cell polarization, migration, and phagocytosis (PMID:16943182, PMID:29186690, PMID:37383235). Through this axis DOCK2 controls immunological synapse formation and TCR/lipid-raft translocation in T cells (PMID:12871644), BCR microcluster growth and plasma cell differentiation in B cells (PMID:29186690, PMID:29503648), lytic synapse formation in NK cells (PMID:23719299), mast cell degranulation via Rac-PAK1 (PMID:36804596), and TLR7/9-driven IFN-α induction in plasmacytoid dendritic cells through Rac-dependent IKKα phosphorylation and IRF-7 nuclear translocation (PMID:20231379). DOCK2 is engaged by diverse upstream receptors and kinases, including the CD3ζ chain of the TCR (PMID:12176041), SYK (which phosphorylates Y985/Y1405 after fungal stimulation) (PMID:35079145), FLT3 (PMID:27748370), ROR1 downstream of Wnt5a (PMID:29678828), and CD11c (PMID:41268550), and its expression is transcriptionally controlled by the TCR-IRF4-SUB1 axis (PMID:41371223). Endogenous inhibition is provided by cholesterol sulfate binding to the DHR-2 domain, a mechanism exploited in the tumor microenvironment to drive CD8+ T cell exhaustion (PMID:30065028, PMID:36626623), and DOCK2 catalysis is pharmacologically blocked by the small molecule CPYPP and by peptides targeting the DOCK2-Rac1 interface (PMID:22520755, PMID:28039053).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 1999 Medium

    Establishing that DOCK2 is a Rac1 activator distinct from focal-adhesion DOCK180 defined it as a candidate hematopoietic-specific Rac regulator.

    Evidence pulldown/binding and Rac1 activation assays with tissue expression analysis

    PMID:10559471

    Open questions at the time
    • No catalytic mechanism or domain responsible for exchange defined
    • No in vivo phenotype
  2. 2001 High

    Genetic deletion showed DOCK2 is the central Rac GEF coupling chemokine receptors to cytoskeletal remodeling in lymphocytes, settling its physiological role.

    Evidence DOCK2 knockout mice with Rac activation, actin polymerization, and chemotaxis assays in T and B cells

    PMID:11518968

    Open questions at the time
    • Receptor-to-DOCK2 coupling mechanism unresolved
    • Membrane recruitment mechanism not addressed
  3. 2002 Medium

    Identification of CD3ζ and CrkL/Vav associations placed DOCK2 within antigen- and adaptor-receptor signaling complexes that activate Rac2 and drive IL-2 transcription.

    Evidence co-immunoprecipitation, Rac activation, and IL-2 promoter reporter assays in Jurkat cells

    PMID:12176041 PMID:12393632

    Open questions at the time
    • Single cell-line Co-IPs without reciprocal validation in primary cells
    • Direct vs. indirect binding not distinguished
  4. 2003 High

    Mapping the ELMO1 interaction to the DOCK2 SH3 domain and showing it is essential for Rac activation defined the obligate DOCK2-ELMO1 functional unit.

    Evidence Co-IP, domain-deletion mutants, and Rac/actin assays in T-hybridoma cells; KO T cells for synapse formation

    PMID:12829596 PMID:12871644

    Open questions at the time
    • Structural basis of SH3-ELMO1 binding not yet defined
    • Whether ELMO1 affects DOCK2 stability not addressed
  5. 2004 High

    Defining a PI3K-largely-independent migration role and identifying HIV-1 Nef hijacking of the DOCK2-ELMO1-Rac complex clarified both physiological and pathogen-manipulated activation routes.

    Evidence double-KO mice with intravital microscopy; proteomic purification and MS of the Nef-associated complex with functional Rac/chemotaxis assays

    PMID:14737186 PMID:15357953

    Open questions at the time
    • Relative contribution of PI3K vs PI3K-independent recruitment unresolved
    • Direct Nef-DOCK2 contact surface not mapped
  6. 2006 High

    Live imaging established that PIP3 recruits DOCK2 to the leading edge in a PI3K-dependent manner, providing the spatial mechanism for polarized Rac activation in neutrophils.

    Evidence DOCK2-/- neutrophils with Rac1/Rac2 assays, live-cell PIP3/F-actin imaging, and PI3K-inhibited translocation assays

    PMID:16943182

    Open questions at the time
    • Lipid-binding determinant on DOCK2 not mapped
    • How dual Rac1/Rac2 selectivity is set is unclear
  7. 2007 High

    Showing DOCK2 controls stathmin phosphorylation, IL-4Rα trafficking, and lymphocyte interstitial motility/egress extended its role beyond chemotaxis into receptor trafficking and Th lineage decisions.

    Evidence DOCK2-/- mice with stathmin phosphorylation, receptor trafficking, Th2 differentiation assays, and multiphoton intravital microscopy

    PMID:17325199 PMID:17767160

    Open questions at the time
    • Direct link from Rac to stathmin phosphorylation not established
    • Mechanism of IL-4Rα lysosomal targeting unresolved
  8. 2008 High

    Cell-type comparisons revealed DOCK2 is required for Rac activation in plasmacytoid but not myeloid dendritic cells, demonstrating lineage-specific Rac-GEF wiring.

    Evidence DOCK2-/- pDC vs mDC Rac activation, chemotaxis, and adoptive transfer assays

    PMID:18198348

    Open questions at the time
    • Identity of the mDC Rac GEF not addressed
    • Basis of pDC-specific dependence unknown
  9. 2010 High

    Linking DOCK2-Rac to IKKα phosphorylation and IRF-7 nuclear translocation defined the signaling route from TLR7/9 nucleic-acid sensing to type I IFN production in pDCs.

    Evidence DOCK2-/- pDCs with Rac, IKKα phosphorylation, IRF-7 translocation assays and dominant-negative Rac rescue

    PMID:20231379

    Open questions at the time
    • How nucleic acid sensing activates DOCK2 TLR-independently is unresolved
    • Direct Rac-to-IKKα link not biochemically defined
  10. 2011 High

    Identifying ASC as a controller of DOCK2 mRNA stability placed DOCK2 expression under inflammasome-adaptor regulation independent of caspase-1.

    Evidence ASC-/- mice, genome-wide mRNA stability analysis, and DOCK2 retroviral rescue of Rac/actin/chemotaxis defects

    PMID:21892172

    Open questions at the time
    • Molecular mechanism by which ASC stabilizes DOCK2 mRNA unknown
  11. 2012 High

    Crystallography, dimerization analysis, and a catalytic-domain inhibitor together defined DOCK2's autoinhibition, the structural basis of mutual relief with ELMO1, and the requirement for DHR-2 dimerization in vivo.

    Evidence 2.1 Å crystal structure of DOCK2-ELMO1 with mutagenesis; lobe A deletion mutants with FRET; CPYPP GEF inhibition and cellular assays

    PMID:22331897 PMID:22520755 PMID:23050005

    Open questions at the time
    • Full-length conformational dynamics not captured at this stage
    • How upstream signals trigger the autoinhibition switch not defined
  12. 2013 High

    Demonstrating that DOCK2 GEF activity is required for NKG2D-driven lytic synapse formation extended its Rac-activating role to NK-cell cytotoxicity.

    Evidence DOCK2-/- and GEF-dead NK cells with killing, lytic synapse, and Rac activation assays plus in vivo BM rejection model

    PMID:23719299

    Open questions at the time
    • Coupling of NKG2D to DOCK2 not biochemically mapped
  13. 2014 High

    Showing ELMO1 prevents DOCK2 polyubiquitination established that complex formation is also a protein-stability mechanism, not merely an activation switch.

    Evidence Elmo1-/- mice, Co-IP, ubiquitination assays, proteasome-inhibitor rescue, and mutant rescue in primary T cells

    PMID:24821968

    Open questions at the time
    • E3 ligase targeting DOCK2 not identified
    • Why Elmo2 cannot substitute is unexplained
  14. 2016 Medium

    Receptor-coupling studies and inhibitory-peptide work connected DOCK2 to FLT3 and JAK/chemokine signaling and validated the DOCK2-Rac1 interface as a druggable surface.

    Evidence MS/Co-IP with FLT3, shRNA functional assays; siRNA with LFA-1/Rac and phosphorylation assays; phage-display peptide GEF inhibition and migration assays

    PMID:27748370 PMID:27986909 PMID:28039053

    Open questions at the time
    • Direct vs scaffold-mediated FLT3-DOCK2 contact not resolved
    • JAK phosphosites on DOCK2 not mapped
  15. 2018 High

    Identifying cholesterol sulfate as an endogenous DHR-2 inhibitor and ROR1 as a Wnt5a-driven recruiter defined both a physiological brake and an oncogenic activation route for DOCK2.

    Evidence in vitro GEF/binding assays, Sult2b1-/- ocular inflammation model; ROR1 P808A mutagenesis with Co-IP and Rac/proliferation assays in CLL

    PMID:29678828 PMID:30065028

    Open questions at the time
    • Cholesterol sulfate binding site on DHR-2 not structurally defined
    • Whether ROR1 recruitment requires ELMO1 not addressed
  16. 2018 High

    B-cell genetics established that PIP3-recruited DOCK2 sustains BCR microcluster growth and is required for plasma cell differentiation and antibody responses.

    Evidence DOCK2-/- and conditional KO B cells with PI3K inhibition, microcluster/F-actin imaging, and in vitro/in vivo plasma cell assays

    PMID:29186690 PMID:29503648

    Open questions at the time
    • Direct effectors linking Rac to BCR microcluster stability not defined
  17. 2020 High

    Cryo-EM of binary and RAC1-ternary complexes provided independent structural confirmation of the closed autoinhibited state and how the open ELMO1 conformation exposes RAC1, RHOG, and BAI-GPCR binding sites.

    Evidence cryo-EM structures, RHOG-ELMO2-RBD crystal structure, and functional mutagenesis

    PMID:32651375

    Open questions at the time
    • Physiological trigger ordering of phosphorylation vs membrane recruitment not resolved
  18. 2020 Medium

    Extending DOCK2-Rac to innate macrophage signaling showed it controls TLR4-induced IKKβ/NF-κB activation and microglial innate immunity, broadening its inflammatory roles.

    Evidence shRNA and CPYPP in macrophages with Rac/IKKβ/NF-κB assays and ALI model; DOCK2-/- microglia functional assays

    PMID:19729484 PMID:33382969

    Open questions at the time
    • Mechanism of TLR4-independent LPS-induced Rac activation unresolved
    • Direct Rac-to-IKKβ link not biochemically defined
  19. 2022 High

    Identifying SYK phosphosites (Y985/Y1405) and a CPYPP-revealed antiviral macrophage role defined post-translational activation and protective innate functions of DOCK2.

    Evidence site-directed mutagenesis with Rac/ROS assays after fungal stimulation; CPYPP in a hamster SARS-CoV-2 model with macrophage and IFN readouts; TGF-β fibrosis model

    PMID:35079145 PMID:35584329 PMID:35940203

    Open questions at the time
    • How phosphorylation couples to DHR-2 conformational change not defined
    • Fibrosis mechanism (Rac-dependence) not fully dissected
  20. 2023 High

    Studies in mast cells, NK/T tumor immunity, neutrophil Rac patterning, CD11c coupling, and FoxM1-driven EMT mapped DOCK2's reach across degranulation, exhaustion, oxidative burst, and epithelial transcription programs.

    Evidence DOCK2-/- mast cells (Rac-PAK1); SULT2B1/cholesterol sulfate HCC models; TIRF-FRET Rac imaging in neutrophils; CD11c-/- phosphoproteomics; DOCK2-FoxM1 Co-IP/ChIP

    PMID:36626623 PMID:36804596 PMID:36883952 PMID:37383235 PMID:41268550

    Open questions at the time
    • Whether nuclear DOCK2-FoxM1 function is Rac-dependent unclear
    • Mechanism of CD11c-driven DOCK2 phosphorylation not mapped
  21. 2025 High

    Identifying the TCR-IRF4-SUB1 axis as a phase-separation-driven transcriptional activator of DOCK2 closed a gap in how DOCK2 expression is induced during T cell activation.

    Evidence conditional Sub1 KO mice with chromatin accessibility, ChIP, phase-separation, reporter assays, Rac/actin readouts, and EAE model

    PMID:41371223

    Open questions at the time
    • How SUB1 condensates select the Dock2 locus specifically not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How upstream phosphorylation, PIP3 recruitment, and ELMO1-mediated conformational opening are integrated into a single ordered activation switch, and how this is differentially tuned across immune lineages, remains unresolved.
  • No unified kinetic model integrating membrane, phospho, and conformational inputs
  • Lineage-specific differences in DOCK2 regulation not mechanistically explained

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 5 GO:0060089 molecular transducer activity 3 GO:0008289 lipid binding 2
Localization
GO:0005886 plasma membrane 3 GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 5 R-HSA-168256 Immune System 5
Partners
CD3ZCRKLELMO1FLT3RAC1RAC2ROR1SYK
Complex memberships
DOCK2-ELMO1 complex

Evidence

Reading pass · 39 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 DOCK2 is essential for lymphocyte chemotaxis: DOCK2-deficient mice show abolished chemokine-induced Rac activation and actin polymerization in T and B lymphocytes, establishing DOCK2 as the central Rac GEF mediating cytoskeletal reorganization downstream of chemokine receptors in lymphocytes. DOCK2 knockout mouse model; Rac activation assay; actin polymerization assay; chemotaxis assay Nature High 11518968
1999 DOCK2 (originally KIAA0209) binds to and activates Rac1, similar to DOCK180, but unlike DOCK180 it does not bind CrkII adaptor, indicating hematopoietic-specific Rac regulation independent of focal adhesion signaling. Pulldown/binding assay; Rac1 activation assay; expression analysis in tissue panels Biochimica et biophysica acta Medium 10559471
2003 DOCK2 associates with ELMO1 through its SH3 domain, and this DOCK2-ELMO1 interaction is required for DOCK2-mediated Rac activation and actin polymerization; a DOCK2 mutant lacking the ELMO1-binding region fails to activate Rac or polymerize actin. Co-immunoprecipitation; DOCK2 domain deletion mutants; Rac activation assay; actin polymerization assay in T-hybridoma cells Blood High 12829596
2003 DOCK2 is essential for TCR-mediated Rac activation and immunological synapse formation; DOCK2-deficient T cells show severely impaired antigen-induced translocation of TCR and lipid rafts (but not PKC-θ or LFA-1) to the APC interface, leading to reduced T cell proliferation. DOCK2 knockout T cells; immunofluorescence of immunological synapse components; antigen-specific proliferation assay Immunity High 12871644
2004 HIV-1 Nef binds the DOCK2-ELMO1 complex (identified by mass spectrometry from T cells) and Rac, and activates Rac by binding this complex; this interaction underlies Nef-mediated inhibition of T cell chemotaxis and promotion of T cell activation. Proteomic purification of Nef-associated complex; mass spectrometry identification; Rac activation assay; chemotaxis assay PLoS biology High 14737186
2004 DOCK2 mediates efficient lymphocyte migration in a largely PI3K-independent manner; a residual PI3K-dependent migration pathway exists (PI3Kγ in T cells, other PI3K isoforms in B cells). DOCK2 is required for integrin activation in B cells but not T cells during chemokine-triggered responses. DOCK2-/- and PI3Kγ-/- mouse models; in vitro adhesion assays; intravital microscopy of lymphoid organ vasculature Immunity High 15357953
2006 DOCK2 regulates motility and polarity during neutrophil chemotaxis by activating both Rac1 and Rac2; DOCK2 associates with PIP3 and translocates to the leading edge of chemotaxing neutrophils in a PI3K-dependent manner, enabling polarized accumulation of F-actin and PIP3. DOCK2-/- neutrophils; Rac1/Rac2 activation assays; live-cell imaging of PIP3 and F-actin localization; translocation assay with PI3K inhibition The Journal of cell biology High 16943182
2007 DOCK2 is required for T cell receptor-mediated phosphorylation of the microtubule-destabilizing protein stathmin and for lysosomal trafficking and degradation of IL-4Rα, thereby controlling Th2 lineage commitment by preventing sustained IL-4R signaling. DOCK2-/- mice; phosphorylation assay for stathmin; IL-4Rα surface expression and lysosomal trafficking assays; Th2 differentiation analysis Nature immunology High 17767160
2007 DOCK2 (and to a lesser extent PI3Kγ) is required for interstitial T and B cell motility within peripheral lymph nodes and for S1P-triggered lymphocyte migration and egress from lymph nodes, as established by multiphoton intravital microscopy. Multiphoton intravital microscopy of DOCK2-/- and PI3Kγ-/- mouse PLNs; S1P-induced migration assay; F-actin and PKB phosphorylation assays The Journal of experimental medicine High 17325199
2008 DOCK2 is required for Rac activation and chemotaxis of plasmacytoid dendritic cells (pDCs) but not myeloid dendritic cells, indicating that pDCs and mDCs use distinct molecules to activate Rac during chemotaxis. DOCK2-/- mouse; Rac activation assay in pDCs and mDCs; chemotaxis assay; adoptive transfer experiments Blood High 18198348
2010 DOCK2 is essential for TLR7- and TLR9-mediated IFN-α induction in plasmacytoid dendritic cells: nucleic acid ligands induce Rac activation through a TLR-independent, DOCK2-dependent mechanism; this Rac activation drives IKK-α phosphorylation and IRF-7 nuclear translocation required for IFN-α production. DOCK2-/- pDCs; Rac activation assay; IKK-α phosphorylation assay; IRF-7 nuclear translocation assay; dominant-negative Rac expression in wild-type pDCs The Journal of experimental medicine High 20231379
2011 The inflammasome adaptor ASC controls mRNA stability and expression of DOCK2 (independently of NLRP3 or caspase-1); ectopic DOCK2 expression in ASC-deficient cells restores Rac-mediated actin polymerization, antigen uptake, and chemotaxis, placing DOCK2 downstream of ASC in adaptive immune cell function. ASC-/- mice; genome-wide mRNA stability analysis; DOCK2 retroviral rescue experiments; Rac activation, actin polymerization, antigen uptake, and chemotaxis assays Nature immunology High 21892172
2012 Crystal structure of the DOCK2-ELMO1 N-terminal complex (2.1 Å) reveals that the C-terminal Pro-rich tail of ELMO1 winds around the SH3 domain of DOCK2 forming an intermolecular five-helix bundle; ELMO1 binding relieves DOCK2 autoinhibition (mediated by interaction between its ELMO-interacting region and DHR-2 domain), and DOCK2 binding simultaneously relieves ELMO1 autoinhibition to permit RhoG binding and membrane localization. X-ray crystallography (2.1 Å); mutagenesis; domain binding assays Proceedings of the National Academy of Sciences of the United States of America High 22331897
2012 CPYPP (4-[3'-(2''-chlorophenyl)-2'-propen-1'-ylidene]-1-phenyl-3,5-pyrazolidinedione) binds reversibly to the DOCK2 DHR-2 catalytic domain and inhibits its GEF activity in vitro; in lymphocytes, CPYPP blocks both chemokine receptor- and antigen receptor-mediated Rac activation, chemotaxis, and T cell activation. In vitro GEF activity assay; compound binding assay to DHR-2; Rac activation assay in lymphocytes; chemotaxis and T cell activation assays Chemistry & biology High 22520755
2012 DOCK2 dimerization via lobe A of the DHR-2 domain is required for effective Rac activation during cell migration; the lobe A deletion mutant retains in vitro GEF activity but fails to activate Rac effectively at the plasma membrane, as shown by FRET analysis, indicating dimerization enables efficient Rac engagement in vivo. DOCK2 lobe A deletion and point mutants; FRET analysis; Rac activation assay; motility and polarity assays in thymoma cells and primary T cells PloS one High 23050005
2002 DOCK2 associates with CrkL (a hematopoietic-specific adaptor) through two separate regions of DOCK2 binding the CrkL SH3 domain; CrkL-induced Rac1 activation is inhibited by a dominant-negative DOCK2 mutant; DOCK2 also associates with Vav GEF in Jurkat cells, suggesting a CrkL-DOCK2-Vav complex regulates Rac1 in leukocytes. Co-immunoprecipitation in vivo and in vitro; Rac1 activation assay; immunocytochemistry colocalization; stable DOCK2 mutant expression in Jurkat cells Blood Medium 12393632
2002 DOCK2 associates with the CD3ζ subunit of the TCR complex in Jurkat cells and activates Rac2; DOCK2-mediated Rac2 activation enhances IL-2 promoter transcriptional activity, and dominant-negative Rac2 suppresses this effect. Co-immunoprecipitation; Rac2 activation assay; IL-2 promoter-luciferase reporter assay; dominant-negative Rac2 expression Biochemical and biophysical research communications Medium 12176041
2013 DOCK2 is required for NK cell-mediated cytotoxicity: DOCK2-deficient NK cells fail to form lytic synapses due to almost complete loss of NKG2D-mediated Rac activation, despite normal conjugate formation with target cells; selective abrogation of DOCK2 GEF activity recapitulates this defect. DOCK2-/- NK cells; in vitro leukemia cell killing assay; in vivo MHC class I-deficient bone marrow rejection model; lytic synapse formation assay; Rac activation assay; GEF-dead DOCK2 mutant Blood High 23719299
2014 Elmo1, but not Elmo2, constitutively interacts with Dock2 in primary T lymphocytes; Elmo1 deficiency reduces Dock2 protein levels ~4-fold by promoting Dock2 polyubiquitination and proteasomal degradation, while Elmo1 overexpression inhibits Dock2 ubiquitination; Elmo1 interaction is required for Dock2-dependent Rac activation and chemotaxis. Elmo1-/- mice; Co-IP in primary T cells; ubiquitination assay; proteasome inhibitor rescue; transfection of Elmo1 mutants; Rac activation and chemotaxis assays Journal of immunology High 24821968
2020 Cryo-EM structures of DOCK2-ELMO1 alone and as a ternary complex with RAC1 show that the binary complex adopts a closed auto-inhibited conformation; conformational change of ELMO1 to an open state exposes RAC1 binding sites on DOCK2-DHR2 and binding sites for RHOG and BAI GPCRs on ELMO1; upstream effectors including DOCK2 and ELMO1 phosphorylation destabilize the auto-inhibited state. Cryo-EM structure determination; crystal structure of RHOG-ELMO2-RBD complex; functional mutagenesis analysis Nature communications High 32651375
2018 Wnt5a induces ROR1 to recruit DOCK2 via the cytoplasmic proline-rich domain (PRD) of ROR1, specifically requiring Pro808; this ROR1-DOCK2 interaction activates Rac1/2 in CLL cells and is required for Wnt5a-driven CLL cell proliferation. Co-immunoprecipitation; ROR1 truncation and point mutants; DOCK2 siRNA knockdown; Rac1/2 activation assay; proliferation assay; cirmtuzumab blocking Blood High 29678828
2018 Cholesterol sulfate (CS) binds to the catalytic DHR-2 domain of DOCK2 and suppresses its GEF activity, inhibiting DOCK2-mediated Rac activation and leukocyte migration; CS is the most abundantly produced in the Harderian gland via SULT2B1b/a sulfotransferases, and Sult2b1 knockout mice show augmented ocular surface inflammation. In vitro GEF activity assay; CS binding assay to DOCK2 DHR-2; mass spectrometric quantification of CS; Sult2b1 knockout mice; ocular inflammation model; leukocyte migration assay Science signaling High 30065028
2017 PIP3-dependent recruitment and activation of DOCK2 at the plasma membrane is required for sustained growth of BCR microclusters through F-actin cytoskeleton remodeling; DOCK2 deficiency disrupts B cell immunological synapse structure. DOCK2-/- B cells; PI3K inhibition; live-cell imaging of BCR microclusters; F-actin assay; B cell immunological synapse imaging Cell reports High 29186690
2018 DOCK2 is required for BCR-mediated Rac activation in B cells; DOCK2-deficient B cells show defects in B cell spreading, sustained BCR microcluster growth, and plasma cell differentiation both in vitro and in vivo, implicating the DOCK2-Rac axis in IgG antibody responses. DOCK2-/- B cells; conditional DOCK2 knockout (B cell lineage); Rac activation assay; B cell spreading assay; BCR microcluster imaging; plasma cell differentiation assay in vitro and in vivo; adoptive transfer Frontiers in immunology High 29503648
2016 DOCK2 co-immunoprecipitates with wild-type FLT3 and FLT3/ITD in leukemia cells; DOCK2 knockdown selectively reduces proliferation and colony formation in leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD cells to cytarabine. Mass spectrometry screen for FLT3-interacting proteins; co-immunoprecipitation; shRNA knockdown; proliferation, colony formation, and cell survival assays; mouse xenograft model Leukemia Medium 27748370
2022 After fungal stimulation, SYK phosphorylates DOCK2 at tyrosine residues Y985 and Y1405, promoting recruitment and activation of Rac GTPases, which increases ROS production and downstream antifungal signaling in macrophages. Phosphorylation assay; site-directed mutagenesis of DOCK2 tyrosine residues; Rac activation assay; ROS production assay; DOCK2-/- macrophages; in vivo fungal infection model Cellular & molecular immunology High 35079145
2016 DOCK2 (together with SOS1 and ARHGEF1) mediates JAK-dependent CXCL12-induced LFA-1 activation and Rac1 activation in human primary T lymphocytes; DOCK2 is tyrosine-phosphorylated upon chemokine signaling in a JAK- and pertussis toxin-sensitive manner. DOCK2 siRNA knockdown; LFA-1 adhesion assay under flow; Rac1 activation assay; tyrosine phosphorylation assay; JAK inhibitor treatment; pertussis toxin pretreatment Journal of immunology Medium 27986909
2023 DOCK2 regulates MRGPRB2-mediated mast cell degranulation through Rac activation and PAK1 phosphorylation; DOCK2-deficient mast cells show impaired MRGPRB2-mediated Rac activation and PAK1 phosphorylation while calcium influx and other signaling molecules are unaffected. DOCK2-/- mice; mast cell degranulation assay (compound 48/80, ciprofloxacin); Rac activation assay; PAK1 phosphorylation assay; calcium flux assay; small-molecule DOCK2 inhibitors; systemic and cutaneous anaphylaxis models The Journal of allergy and clinical immunology High 36804596
2023 Cholesterol sulfate synthesized by SULT2B1 in tumor cells suppresses DOCK2 enzymatic GEF activity in T cells, promoting CD8+ T cell exhaustion in the HCC tumor microenvironment; tolazamide reverses DOCK2 inactivation-mediated T cell exhaustion. Quasi-targeted metabolomics; mass spectrometry; mass cytometry (CyTOF); DOCK2 GEF activity assay; flow cytometry; mouse HCC models; virtual screening and molecular docking Hepatology Medium 36626623
2023 DOCK2 generates characteristic spatiotemporal patterns of Rac activity (visualized by live TIRF-FRET imaging in primary neutrophils) that are specifically required for neutrophil polarization, random migration, chemotaxis speed and turning, and rapid phagocytosis; Dock2 deficiency abolishes these spatially distinct Rac pools at leading edges. Live TIRF-FRET imaging with Rac-FRET reporter mice; DOCK2-/-, Tiam1-/-, Prex1-/-Vav1-/- neutrophils; polarization, migration velocity, chemotaxis, and phagocytosis assays; in vivo peritonitis model Frontiers in immunology High 37383235
2025 The transcription factor SUB1, induced by the TCR-IRF4 axis, directly trans-activates DOCK2 transcription by forming liquid-liquid phase separation condensates that open chromatin at the Dock2 locus and partners with JUNB to amplify Dock2 expression; conditional Sub1 deletion reduces DOCK2 expression, impairs Rac-dependent actin polymerization and T cell motility, and prevents experimental autoimmune encephalomyelitis. Conditional T cell-specific Sub1 KO mice; chromatin accessibility assay; ChIP; phase separation assay; transcriptional reporter assay; DOCK2 expression assay; Rac activation; actin polymerization; EAE model Immunity High 41371223
2025 CD11c (integrin αX) physically associates with DOCK2 intracellularly in neutrophils (confirmed by co-immunoprecipitation and proteomics); CD11c-deficient neutrophils show reduced DOCK2 phosphorylation and impaired Rac activation, leading to selective defects in ROS/NADPH oxidase activity without affecting phagocytosis. Phosphoproteomic profiling of CD11c-/- neutrophils; co-immunoprecipitation + proteomics; ROS production assay; phagocytosis assay Frontiers in immunology Medium 41268550
2016 Inhibitory peptides discovered by T7 phage display bind the DOCK2 catalytic domain and block DOCK2-Rac1 protein-protein interaction at nanomolar concentrations; cell-penetrating peptide conjugation enables intracellular delivery and inhibition of B cell migration (IC50 ~120 nM). Random peptide T7 phage display; in vitro DOCK2 GEF inhibition assay; cell migration assay; cellular internalization assay Biochemical and biophysical research communications Medium 28039053
2022 DOCK2 inhibition with CPYPP increased severity of SARS-CoV-2 pneumonia in a Syrian hamster model, characterized by impaired macrophage recruitment and dysregulated type I interferon responses, demonstrating that DOCK2 function is required for macrophage-mediated antiviral immunity. DOCK2 inhibitor (CPYPP) treatment in Syrian hamster SARS-CoV-2 model; viral load measurement; macrophage recruitment assay; type I IFN response assay Nature Medium 35940203
2022 DOCK2 promotes TGF-β-induced fibroblast-to-myofibroblast transition (FMT) in lung fibroblasts; TGF-β upregulates DOCK2 expression via both Smad3 and ERK pathways and also stabilizes DOCK2 protein; DOCK2 knockdown attenuates α-SMA, collagen-1, and fibronectin induction; DOCK2-/- mice are protected from bleomycin-induced pulmonary fibrosis. DOCK2 siRNA knockdown in primary human lung fibroblasts; Smad3/ERK inhibitors; DOCK2-/- mouse bleomycin model; Western blot for FMT markers American journal of physiology. Cell physiology Medium 35584329
2023 DOCK2 interacts with transcription factor FoxM1 and enhances FoxM1 binding to mesenchymal marker gene promoters, promoting mesenchymal marker gene transcription and EMT in airway epithelial cells downstream of TGF-β1 stimulation. DOCK2-FoxM1 co-immunoprecipitation; ChIP assay for FoxM1 promoter binding; DOCK2 KD and overexpression; TGF-β1-induced EMT assay; DOCK2-/- HDM-induced asthma mouse model American journal of respiratory cell and molecular biology Medium 36883952
2020 DOCK2-mediated Rac activation is required for TLR4-induced inflammatory responses in macrophages; LPS induces Rac activation through a TLR4-independent, DOCK2-dependent mechanism; DOCK2-Rac signaling controls IKKβ activation and NF-κB nuclear translocation for inflammatory cytokine release. Ad-shDOCK2 macrophages; Rac activation assay; IKKβ phosphorylation assay; NF-κB nuclear translocation assay; CPYPP pharmacological inhibition; LPS-induced ALI mouse model Biochemical pharmacology Medium 33382969
2009 DOCK2 is expressed specifically in microglia in the brain and regulates microglial innate immunity (cytokine secretion, phagocytosis, paracrine neurotoxicity) independently of COX2 induction; DOCK2 links to prostaglandin E2 receptor EP2 signaling in the brain. Immunohistochemistry of human AD brain; DOCK2-/- microglial functional assays (cytokine, phagocytosis, neurotoxicity); EP2-DOCK2 pathway analysis The American journal of pathology Medium 19729484
2020 Wnt5a induces ERK1/2 phosphorylation and CLL cell proliferation via ROR1/DOCK2-dependent pathway; DOCK2 siRNA knockdown blocks Wnt5a-induced ERK1/2 phosphorylation, and ROR1P808A (unable to recruit DOCK2) fails to mediate these effects; ibrutinib cannot inhibit this Wnt5a-ROR1-DOCK2-ERK1/2 axis. DOCK2 siRNA; ROR1 mutants (ΔPRD, P808A); ERK1/2 phosphorylation assay; DOCK2 phosphorylation assay; CLL cell proliferation assay Leukemia Medium 33097837

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2022 CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic acids research 1178 35609983
2001 Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 361 11518968
2004 Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity 187 15357953
2006 DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis. The Journal of cell biology 170 16943182
2015 Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. The New England journal of medicine 160 26083206
2007 A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. The Journal of experimental medicine 126 17325199
2004 HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. PLoS biology 107 14737186
2003 DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-theta and LFA-1, in T cells. Immunity 107 12871644
2010 Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation. The Journal of experimental medicine 98 20231379
2011 The inflammasome adaptor ASC regulates the function of adaptive immune cells by controlling Dock2-mediated Rac activation and actin polymerization. Nature immunology 96 21892172
2003 DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1. Blood 95 12829596
2022 DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature 77 35940203
2002 The CDM protein DOCK2 in lymphocyte migration. Trends in cell biology 77 12191913
1999 Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins. Biochimica et biophysica acta 74 10559471
2012 Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses. Proceedings of the National Academy of Sciences of the United States of America 72 22431588
2012 Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2. Chemistry & biology 71 22520755
2012 Structural basis for mutual relief of the Rac guanine nucleotide exchange factor DOCK2 and its partner ELMO1 from their autoinhibited forms. Proceedings of the National Academy of Sciences of the United States of America 68 22331897
2007 T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2. Nature immunology 68 17767160
2002 DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 63 12393632
2009 CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood 59 19451552
2008 Differential requirement for DOCK2 in migration of plasmacytoid dendritic cells versus myeloid dendritic cells. Blood 59 18198348
2013 The Rac activator DOCK2 regulates natural killer cell-mediated cytotoxicity in mice through the lytic synapse formation. Blood 50 23719299
2010 PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Molecular cancer 50 20412587
2020 Structure of the DOCK2-ELMO1 complex provides insights into regulation of the auto-inhibited state. Nature communications 49 32651375
2014 Essential role of Elmo1 in Dock2-dependent lymphocyte migration. Journal of immunology (Baltimore, Md. : 1950) 45 24821968
2013 Phenotype and function of B cells and dendritic cells from interferon regulatory factor 5-deficient mice with and without a mutation in DOCK2. International immunology 45 23291967
2018 Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 44 29678828
2018 Dock2 in the development of inflammation and cancer. European journal of immunology 42 29509960
2009 DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain. The American journal of pathology 42 19729484
2005 Deletion of DOCK2, a regulator of the actin cytoskeleton in lymphocytes, suppresses cardiac allograft rejection. The Journal of experimental medicine 40 16230477
2023 SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology (Baltimore, Md.) 39 36626623
2024 Protein-Ligand Blind Docking Using CB-Dock2. Methods in molecular biology (Clifton, N.J.) 38 37676595
2018 Cholesterol sulfate is a DOCK2 inhibitor that mediates tissue-specific immune evasion in the eye. Science signaling 36 30065028
2020 Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism. Leukemia 35 33097837
2020 DOCK2 contributes to endotoxemia-induced acute lung injury in mice by activating proinflammatory macrophages. Biochemical pharmacology 32 33382969
2019 Human DOCK2 Deficiency: Report of a Novel Mutation and Evidence for Neutrophil Dysfunction. Journal of clinical immunology 32 30838481
2006 DOCK2 is required for chemokine-promoted human T lymphocyte adhesion under shear stress mediated by the integrin alpha4beta1. Journal of immunology (Baltimore, Md. : 1950) 31 17015707
2017 Growth of B Cell Receptor Microclusters Is Regulated by PIP2 and PIP3 Equilibrium and Dock2 Recruitment and Activation. Cell reports 30 29186690
2013 Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Experimental and molecular pathology 29 23318649
2006 DOCK2 is required in T cell precursors for development of Valpha14 NK T cells. Journal of immunology (Baltimore, Md. : 1950) 29 16585555
2012 Dimerization of DOCK2 is essential for DOCK2-mediated Rac activation and lymphocyte migration. PloS one 28 23050005
2014 Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2. PloS one 27 25076492
2010 DOCK2 regulates cell proliferation through Rac and ERK activation in B cell lymphoma. Biochemical and biophysical research communications 25 20350533
2002 DOCK2 mediates T cell receptor-induced activation of Rac2 and IL-2 transcription. Biochemical and biophysical research communications 25 12176041
2022 DOCK2 regulates antifungal immunity by regulating RAC GTPase activity. Cellular & molecular immunology 23 35079145
2016 DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells. Leukemia 23 27748370
2022 DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition. American journal of respiratory cell and molecular biology 22 34710342
2022 DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition. American journal of physiology. Cell physiology 22 35584329
2022 Insights from DOCK2 in cell function and pathophysiology. Frontiers in molecular biosciences 22 36250020
2018 The Rac Activator DOCK2 Mediates Plasma Cell Differentiation and IgG Antibody Production. Frontiers in immunology 22 29503648
2016 Novel DOCK2-selective inhibitory peptide that suppresses B-cell line migration. Biochemical and biophysical research communications 21 28039053
2019 T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. The Journal of allergy and clinical immunology 20 30826364
2021 Dedicator of Cytokinesis 2 (DOCK2) Deficiency Attenuates Lung Injury Associated with Chronic High-Fat and High-Fructose Diet-Induced Obesity. The American journal of pathology 19 34767813
2017 DOCK2 deficiency mitigates HFD-induced obesity by reducing adipose tissue inflammation and increasing energy expenditure. Journal of lipid research 19 28716822
2014 DOCK2 is critical for CD8(+) TCR(-) graft facilitating cells to enhance engraftment of hematopoietic stem and progenitor cells. Stem cells (Dayton, Ohio) 18 25044556
2016 SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines. Journal of immunology (Baltimore, Md. : 1950) 17 27986909
2023 DOCK2 regulates MRGPRX2/B2-mediated mast cell degranulation and drug-induced anaphylaxis. The Journal of allergy and clinical immunology 16 36804596
2018 B Cell Defects Observed in Nod2 Knockout Mice Are a Consequence of a Dock2 Mutation Frequently Found in Inbred Strains. Journal of immunology (Baltimore, Md. : 1950) 14 30012848
2017 Current Status of Dedicator of Cytokinesis-Associated Immunodeficiency: DOCK8 and DOCK2. Dermatologic clinics 14 27890234
2023 DOCK2 Promotes Asthma Development by Eliciting Airway Epithelial-Mesenchymal Transition. American journal of respiratory cell and molecular biology 13 36883952
2021 The role of Dock2 on macrophage migration and functions during Citrobacter rodentium infection. Clinical and experimental immunology 13 33662140
2019 DOCK2 Sets the Threshold for Entry into the Virtual Memory CD8+ T Cell Compartment by Negatively Regulating Tonic TCR Triggering. Journal of immunology (Baltimore, Md. : 1950) 13 31740487
2007 Dock2 participates in bone marrow lympho-hematopoiesis. Biochemical and biophysical research communications 13 18157938
2021 Dock2 affects the host susceptibility to Citrobacter rodentium infection through regulating gut microbiota. Gut pathogens 12 34391464
2017 Antigen Availability and DOCK2-Driven Motility Govern CD4+ T Cell Interactions with Dendritic Cells In Vivo. Journal of immunology (Baltimore, Md. : 1950) 12 28607113
2023 Multiple Immune Defects in Two Patients with Novel DOCK2 Mutations Result in Recurrent Multiple Infection Including Live Attenuated Virus Vaccine. Journal of clinical immunology 11 36947335
2009 Role of DOCK2 and DOCK180 in fetal thymus colonization. European journal of immunology 10 19728314
2023 Dock2 generates characteristic spatiotemporal patterns of Rac activity to regulate neutrophil polarisation, migration and phagocytosis. Frontiers in immunology 9 37383235
2021 Genetic variants of DOCK2, EPHB1 and VAV2 in the natural killer cell-related pathway are associated with non-small cell lung cancer survival. American journal of cancer research 9 34094683
2020 DOCK2 couples with LEF-1 to regulate B cell metabolism and memory response. Biochemical and biophysical research communications 9 32703426
2025 Inhibition of RAC1 activator DOCK2 ameliorates cholestatic liver injury via regulating macrophage polarisation and hepatic stellate cell activation. Biology direct 8 39923106
2024 DOCK2 Deficiency Causes Defects in Antiviral T-Cell Responses and Impaired Control of Herpes Simplex Virus Infection. The Journal of infectious diseases 8 38366567
2023 DOCK2 Promotes Atherosclerosis by Mediating the Endothelial Cell Inflammatory Response. The American journal of pathology 8 37838011
2021 First patient in the Iranian Registry with novel DOCK2 gene mutation, presenting with skeletal tuberculosis, and review of literature. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 8 34872585
2017 Investigation on cellular uptake and pharmacodynamics of DOCK2-inhibitory peptides conjugated with cell-penetrating peptides. Bioorganic & medicinal chemistry 8 28284862
2024 Silencing DOCK2 Attenuates Cardiac Fibrosis Following Myocardial Infarction in Mice Via Targeting PI3K/Akt and Wnt/β-Catenin Pathways. Journal of cardiovascular translational research 7 38990461
2022 Dedicator of Cytokinesis 2 (DOCK2) Silencing Protects Against Cerebral Ischemia/Reperfusion by Modulating Microglia Polarization via the Activation of the STAT6 Signaling Pathway. Neuroscience 7 35395356
2021 Hematopoietic stem cell transplantation complicated with EBV associated hemophagocytic lymphohistiocytosis in a patient with DOCK2 deficiency. The Turkish journal of pediatrics 7 35023658
2023 DOCK2 Deficiency Attenuates Abdominal Aortic Aneurysm Formation-Brief Report. Arteriosclerosis, thrombosis, and vascular biology 6 37021575
2020 miR-16 exhibits protective function in LPS-treated cardiomyocytes by targeting DOCK2 to repress cell apoptosis and exert anti-inflammatory effect. Cell biology international 6 32369253
2022 Association of a Novel DOCK2 Mutation-Related Gene Signature With Immune in Hepatocellular Carcinoma. Frontiers in genetics 5 35620462
2024 Loss of DOCK2 potentiates Inflammatory Bowel Disease-associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression. Oncogene 4 39242821
2022 Extra-hematopoietic immunomodulatory role of the guanine-exchange factor DOCK2. Communications biology 4 36380073
2025 DOCK2 Deficiency and GATA2 Haploinsufficiency Can Underlie Critical Coronavirus Disease 2019 (COVID-19) Pneumonia. Journal of clinical immunology 3 40153067
2023 DOCK2 Mutation and Recurrent Hemophagocytic Lymphohistiocytosis. Life (Basel, Switzerland) 3 36836791
2022 DOCK2 and phosphoinositide-3 kinase δ mediate two complementary signaling pathways for CXCR5-dependent B cell migration. Frontiers in immunology 3 36341455
2019 Spontaneous Loss-of-Function Dock2 Mutation Alters Murine Colitis Sensitivity and Is a Confounding Variable in Inflammatory Bowel Disease Research. Crohn's & colitis 360 3 39624652
2024 Correction to: Spontaneous Loss-of-Function Dock2 Mutation Alters Murine Colitis Sensitivity and Is a Confounding Variable in Inflammatory Bowel Disease Research. Crohn's & colitis 360 2 39347442
2024 Single-Cell Transcriptomics Reveals a Pivotal Role of DOCK2 in Sjögren Disease. ACR open rheumatology 2 39382155
2024 DOCK2 deficiency alleviates neuroinflammation and affords neuroprotection after spinal cord injury. Biochimica et biophysica acta. Molecular cell research 2 39603464
2026 The PTBP1-EZH2-DOCK2 axis promotes M1 microglial polarization and exacerbates neuronal apoptosis following spinal cord injury. Journal of orthopaedic translation 1 41836556
2025 Dock2 deficiency reveals abnormal activation and differentiation of T cells under the physiological condition. Molecular immunology 1 40101338
2025 DOCK2 protects against bacterial sepsis by constraining T helper 1 response. Frontiers in immunology 1 40510337
2025 DOCK2 in Disease: Emerging Insights and Research Advances. Immunological investigations 1 41369116
2026 Temporal Proteomic and Phosphoproteomic Profiling Deciphers Molecular Dynamics of Acute-to-Chronic Kidney Disease After Ischemia-Reperfusion Injury, With Dock2 Emerging as a Key Regulator. Molecular & cellular proteomics : MCP 0 41534628
2026 Heterozygous variants in DOCK2 leading to susceptibility to viral illnesses. The Journal of allergy and clinical immunology 0 41654261
2026 Dock2 Protects Colitis by Facilitating Akkermansia Colonization via Suppressing IL-22-Reg3 Activity. Inflammation 0 42020880
2025 DOCK2 as a novel CD11c ligand in neutrophils to regulate reactive oxygen species production. Frontiers in immunology 0 41268550
2025 The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. Immunity 0 41371223
2023 DOCK2-deficiency causes defects in anti-viral T cell responses and poor control of herpes simplex virus infection. bioRxiv : the preprint server for biology 0 37577614

Missed literature

Know a paper Affinage missed for DOCK2? Flag it for the maintainers and the community.

No submissions yet.